乌司他丁联合胸腺肽对脓毒血症患者免疫调理的临床研究  

Clinical Study of Ulinastatin and Thymosin on Immune-modulation in Septic Patients

作　　者：韩宇[1] 张素梅[1] 施锐[1] 

机构地区：[1]安徽省六安市人民医院重症医学科,安徽六安237005

出　　处：《河北医学》2016年第9期1409-1411,共3页Hebei Medicine

基　　金：国家自然科学基金青年科学基金项目;(编号:81201907)

摘　　要：目的:研究乌司他丁联合胸腺肽对脓毒血症患者免疫调理的临床效果。方法:选取2009年1月至2015年12月安徽省六安市人民医院ICU脓毒症患者40例,随机分为治疗组和对照组,各20例。对照组采用经典SSC治疗,治疗组在上述治疗基础上,加用乌司他丁和胸腺肽联合免疫调理治疗。观察治疗前和治疗后4、7d的C反应蛋白(CRP)的动态变化,比较患者的慢性健康评分系统(APACHE-Ⅱ)评分、器官功能障碍评分(MODS评分)。结果:疗后治疗组C反应蛋白、APACHE-Ⅱ及MODS评分显著下降(p<0.05)。结论:联合应用胸腺肽和乌司他丁治疗脓毒症,可提高患者免疫力,显著降低C反应蛋白、APACHE-Ⅱ及MODS评分,改善患者病情。Objective： To study the clinical effect of immune-modulation therapy of ulinastatin and thy- mosin in the treatment of sepsis. Methods： 40 patients with sepsis admitted to ICU from Jan.2009 to Dec.2015 were divided into two groups randomly, therapy group and control group. The control group was given routine therapy, while the therapy group was given routine therapy of thymosin and ulinastatin. The dynamic change of C-reactive protein in therapy group were observed before and after therapy on the 4th and 7th day. The score of MODS and APACHIE- Ⅱ were observed. Results： After treatment, the levels of C-reactive protein and the score of MODS and APACHIE-Ⅱ after therapy on the 4th and 9th day decreased significantly. Conclusion： Treating the patients with thymosin and ulinastatin can raise their immunity, decrease the levels of CRP and A- PACHE Ⅱ and MODS score and improve their prognosis.

关 键 词：脓毒症 乌司他丁 胸腺肽 C反应蛋白 APACHE-Ⅱ评分 MODS评分 

分 类 号：R459.7[医药卫生—急诊医学]